Related Experiment Video
Updated: Jul 2, 2025

07:26
Isolation of Functional Cardiac Immune Cells
Published on: December 5, 2011
15.1K
Mast Cells in Cardiac Remodeling: Focus on the Right Ventricle
Argen Mamazhakypov1, Abdirashit Maripov2, Akpay S Sarybaev2
1Department of Internal Medicine, Excellence Cluster Cardio-Pulmonary Institute (CPI), Member of the German Center for Lung Research (DZL), Justus Liebig University of Giessen, 35392 Giessen, Germany.
Journal of Cardiovascular Development and Disease
|February 23, 2024
Summary
Mast cells contribute to right ventricle (RV) remodeling and failure. Targeting these cells may offer new therapies for RV remodeling, an area lacking specific treatments.
Area of Science:
- Cardiovascular Biology
- Immunology
- Cardiac Pathophysiology
Background:
- Cardiac chambers remodel in response to stressors.
- Right ventricle (RV) remodeling due to overload leads to failure and mortality.
- RV remodeling is less understood than left ventricular remodeling, with no specific therapies.
Purpose of the Study:
- To review the role of mast cells in cardiac remodeling.
- To focus on mast cell involvement in RV remodeling.
- To explore mast cell-targeted therapies for RV remodeling.
Main Methods:
- Literature review of experimental findings.
- Analysis of mast cell mediators (inflammatory mediators, growth factors, proteases).
- Examination of therapeutic interventions targeting mast cells.
Main Results:
- Mast cells play a significant role in adverse cardiac remodeling.
- Mast cell mediators adversely affect cardiac cells, contributing to remodeling.
- Mast cells are emerging as a potential therapeutic target for RV remodeling.
Conclusions:
- Mast cells are implicated in RV remodeling and failure.
- Targeting mast cells may mitigate adverse RV remodeling.
- Further research into mast cell-targeted therapies is warranted for RV diseases.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Structure of Cardiac Muscles
11.0K
Cardiac muscle, or myocardium, is a specialized type of muscle found exclusively in the heart. Its unique structural and functional characteristics enable the heart to perform its vital role of pumping blood throughout the body continuously and rhythmically. The cardiac muscle cells, or cardiomyocytes, possess an endomysium and perimysium but do not have an epimysium.
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
11.0K

